Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Raez, L. E. [1 ]
Baca, Y. [2 ]
Nagasaka, M. [3 ]
Nieva, J. [4 ]
Mandani, H. [5 ]
Wanderwalde, A. [6 ]
Borghaei, H. [7 ]
Naban, C.
Langer, C. [8 ,9 ]
Socinsky, M. A. [10 ]
Lopes, G. [11 ]
Khan, H. [12 ]
Wozniak, A. [13 ]
Carracedo, C. [14 ]
Liu, S. [15 ]
机构：
[1] Florida Atlantic Univ, Mem Canc Inst, Miami, FL USA
[2] Caris Life Sci, Irving, TX USA
[3] Univ Calif Irvine, Orange, CA USA
[4] Univ Southern Calif, Los Angeles, CA USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Caris Life Sci, Irvine, CA USA
[7] Fox Chase Canc Ctr, Philadelphia, PA USA
[8] Caris Life Sci, Dallas, TX USA
[9] Univ Penn, Philadelphia, PA USA
[10] Advent Hlth Orlando, Orlando, FL USA
[11] Univ Miami, Miami, FL USA
[12] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[13] UPMC, Hillman Canc Ctr, Philadelphia, PA USA
[14] Florida Atlantic Univ, Mem Canc Inst, Pembroke Pines, FL USA
[15] Georgetown Univ, Washington, DC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR; Next Generation Sequencing; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP16.03-02
引用
收藏
页码：S597 / S597
页数：1
相关论文
共 50 条
  • [21] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] TUMOR BURDEN AND TYROSINE KINASE INHIBITORS (TKI) BENEFIT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR SENSITIZING MUTATIONS (EGFRM) AND ALK REARRANGEMENT (ALK plus )
    Leduc, C.
    Moussa, N.
    Faivre, L.
    Biondani, P.
    Pignon, J.
    Caramella, C.
    Besse, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S37 - S37
  • [23] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin
    Jin, Bo
    Chu, Tianqing
    Dong, Xue
    Yang, Haitang
    Zhang, Yanwei
    Wu, Dan
    Lou, Yuqing
    Zhang, Xueyan
    Wang, Huiming
    Han, Baohui
    [J]. LUNG CANCER, 2016, 96 : 87 - 92
  • [24] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [25] Impact of EGFR tyrosine kinase domain mutations on adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC)
    Tsao, Ming S.
    Sakurada, Akira
    Aviel-Ronen, Sarit
    Ding, Keyue
    Liu, Ni
    Gandara, David R.
    Johnson, David H.
    Rigas, James R.
    Seymour, Lesley
    Shepherd, Frances A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S351 - S352
  • [26] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
    Singh, Mahaveer
    Jadhav, Hemant R.
    [J]. DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
  • [27] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
  • [28] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [29] A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
    Enrico, D. H.
    Lacroix, L.
    Rouleau, E.
    Scoazec, J-Y
    Loriot, Y.
    Tselikas, L.
    Jovelet, C.
    Planchard, D.
    Gazzah, A.
    Mezquita, L.
    Ngo, M.
    Michiels, S.
    Maillard, A.
    Massard, C.
    Facchinetti, F.
    Soria, J-C
    Andre, F.
    Vassal, G.
    Friboulet, L.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [30] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345